Pharmaceutical company CorMedix announced that it has been granted a patent from the European Patent Office for Neutrolin, its low heparin catheter lock solution. Sometimes called "the Prosl patent," the solution maintains patency and prevents infection in a hemodialysis catheter. CorMedix is the exclusive global licensee of European Patent EP 1 814 562 B1, which was granted on Jan. 8.
This issuance of the Prosl patent adds significantly to the company's intellectual property portfolio in the European Union. The patent will strengthen CorMedix's ability to compete with its catheter lock solutions and help raise Europe's standard of care for catheters.
CorMedix is a pharmaceutical company focused on developing and commercializing therapeutic products for preventing and treating cardio-renal and infectious disease. The company's first commercial product is Neutrolin, which is a catheter lock solution that prevents catheter-related bloodstream infections and maintains catheter patency in tunneled, cuffed, central venous catheters that are used for vascular access in hemodialysis patients.
For more information, visit cormedix.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com